# Menopause Market

> Menopause Market Research Report: Information by Treatment Type (Hormone Therapy, Non-Hormonal Treatment, and dietary supplements), By Menopause Stage (menopause, perimenopause, and post-menopause), By Application (Hot Flashes and Night Sweats (Vasomotor Symptoms), Vaginal Dryness and Atrophy, Sleep Disturbances, Mood Swings and Depression, Bone Health, and Urinary Symptoms), By Distribution Channel (hospital pharmacy, retail pharmacy, and online channels.)By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) -Global Forecast to 2035.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.7%
- **2024:** $ 16,994.32 Million
- **2035:** $ 30,415.7 Million
- **Key Players:** Companies such Sparton Corporation, Thales Group, ASELSAN A.Ş., Bharat Dynamics Limited (BDL), L3Harris Technologies, Inc, Radixon Group, Ultra Group are some of the major participants in the global market.

**Report ID:** MRFR/HC/66570-CR · **Pages:** 128 · **Author:** Snehal Singh & Rahul Gotadki · **Last Updated:** May 08, 2026

**URL:** https://www.marketresearchfuture.com/reports/menopause-market-68370

---

## Market Drivers

### Shift Towards Non-Hormonal and Dietary Supplements

The increasing shift toward non-hormonal therapies and dietary supplements as a primary approach to managing menopause symptoms is a significant growth driver for the Menopause Market. Women seeking alternatives to hormone replacement therapy (HRT), which has been associated with certain health risks such as an increased likelihood of breast cancer and cardiovascular conditions, are increasingly turning to natural and dietary options.
 

- According to WHO, nearly 75% of menopausal women experience symptoms requiring medical or lifestyle intervention, while PAHO reports that cardiovascular diseases remain the leading cause of death among women in the Americas, accounting for over 1.9 million deaths annually.

### Expanding acceptance of hormone therapy (HT) post-WHI re-evaluation

The expanded acceptance of hormone therapy (HT) following the re-evaluation of findings from the Women's Health Initiative (WHI) has significantly influenced the Menopause Market. The WHI, initially launched in 1991, aimed to evaluate the health benefits and risks of HT in postmenopausal women.
 
Moreover, advancements in formulations such as bioidentical hormones and transdermal delivery systems offer safer and more personalized treatment options, further driving acceptance. Regulatory bodies, including the U.S. Food and Drug Administration (FDA), have also updated guidelines to reflect current evidence, supporting more informed decision-making. 
 
Overall, the re-evaluation of WHI data has led to a more balanced perspective, fostering greater confidence among both patients and clinicians in the use of hormone therapy, and thereby supporting the continued growth of the global market.
 

- According to CDC-supported clinical findings, approximately 80% of women experience menopause-related vasomotor symptoms, while WHO data shows global female life expectancy reached nearly 76 years in 2023.

## Future Outlook

The Menopause Industry size is projected to reach USD 30,415.70 million by 2035, growing at a CAGR of 5.7%, driven by increasing demand for high-performance computing and enhanced security features.

**New opportunities:**

- Development of Non-Hormonal Therapies. Focus on Menopause at the Workplace.

## Segment Insights

### By Treatment Type: Hormone Therapy (largest market) vs Non-Hormonal Treatment (fastest growing)

Based on treatment, the Menopause Market has been segmented into Hormone Therapy, Non-Hormonal Treatment, and dietary supplements. The Hormone Therapy****segment held the largest market share at 46.8% in 2025, and the Non-Hormonal Therapy segment is the fastest growing segment during the forecast period.

### By Menopause Stage: perimenopause (largest market) vs post menopause (fastest-growing)

Based on menopause stage, the industry has been segmented into premature menopause, perimenopause, and postmenopause. The Perimenopause****segment held the largest Menopause Market in 2025 with 48.6% , and the Perimenopause segment is the fastest growing segment during the forecast period.

### By Application: Hot Flashes and Night Sweats (largest market) vs Bone Health (fastest-Growing)

Based on application, the Menopause Market has been segmented into Hot Flashes and Night Sweats (Vasomotor Symptoms), Vaginal Dryness and Atrophy, Sleep Disturbances, Mood Swings and Depression, Bone Health, and Urinary Symptoms. The Hot Flashes and Night Sweats (Vasomotor Symptoms)****segment held the largest market in 2025 with 38.9% share, and the Sleep Disturbances segment is the fastest growing segment during the forecast period.

### By Distribution channel: hospital pharmacy (largest market) vs retail pharmacy (fastest-Growing)

Based on distribution channel, the Menopause Market has been segmented into hospital pharmacy, retail pharmacy, and online channels. The Hospital Pharmacies****segment held the largest market share in 2025 at 44.5, and the Online Channels segment is the fastest growing segment during the forecast period.

## Regional Market Share Analysis

### North America**:**Expanding high consumer engagement

North America leads in the Menopause Market size, accounting for over 42.09% of the global revenue in 2024. North America remains the global leader in the global market, supported by strong healthcare infrastructure, widespread education, and high consumer engagement.

- According to the CDC, nearly 6,000 women in the United States enter menopause every day, equivalent to over 2 million women annually. Additionally, WHO data indicates female life expectancy in North America exceeds 80 years, significantly increasing long-term demand for menopause symptom management, preventive healthcare services, and personalized treatment solutions across the region.

The U.S. accounts for the vast majority of this regional share. Market dynamics are characterized by a robust demand for both traditional hormone replacement therapies (HRT) and an expanding segment of non-hormonal, prescription-based alternatives. Telemedicine has emerged as a critical driver, facilitating easier access to specialized care and reducing the stigma often associated with menopausal health.

### Europe: Strong Production high rates of clinical diagnosis

Europe Menopause Market size was valued at USD 5098.30 million in 2024, making it the second-largest regional market with a 30% share. Europe follows as a significant market, bolstered by comprehensive public healthcare systems that often subsidize menopause-related treatments, such as HRT in the UK and various EU nations. This structured access encourages high rates of clinical diagnosis and sustained treatment adherence. 

- According to WHO Europe statistics, women aged 50 years and older account for more than 35% of Europe’s female population, while ECDC public health data highlights increasing healthcare utilization among aging women across EU countries.

Dietary supplements represent the largest revenue segment, as many women lean toward holistic and over-the-counter solutions alongside conventional medical care. The region is seeing a steady, moderate growth trajectory as it integrates advanced digital health solutions with existing clinical networks.

### Asia Pacific: Growing escalating health consciousness

The APAC region is positioned for the most significant growth, driven by a massive, aging female population and a rapid rise in health consciousness. Market expansion here is unique due to the intersection of Western medical approaches with traditional practices like acupuncture and herbal medicine.

Dietary supplements focused on brain, heart, and bone health are seeing high consumer uptake, supported by the proliferation of e-commerce platforms. Efforts to increase societal awareness and reduce cultural stigma are further accelerating the adoption of menopause-specific wellness products.

### South America: Protection of health access

South America represents an emerging frontier in the menopause market. Growth is driven by an aging demographic that is increasingly vocal about their specific healthcare needs. Similar to other emerging regions, there is a strong focus on affordable, accessible over-the-counter options and dietary supplements. As awareness grows through local health advocacy and the expansion of digital health access, the region is poised for continued, incremental growth, bridging the gap between historical medical neglect and modern, proactive management.

### Middle East & Africa: Emerging health access

The Middle East & Africa (MEA) region is emerging as a steady but smaller sonobuoy market, driven by maritime security imperatives and strategic waterways protection requirements. Countries such as Saudi Arabia, the United Arab Emirates, and Egypt have been expanding sonar and sonobuoy systems to monitor areas like the Persian Gulf and Red Sea, where piracy, border security, and critical shipping routes demand enhanced underwater surveillance.

South Africa also contributes through coastal monitoring and research activities. While overall market share is lower compared to North America and Europe, MEA growth reflects increased defense spending, naval modernization, and a rising focus on maritime situational awareness. As regional actors pursue infrastructure protection and joint security initiatives, sonobuoys serve as critical acoustic sensors for ASW and surveillance missions across strategic chokepoints.

## Competitive Benchmarking

Many global, regional, and local vendors characterize the Menopause Market. The global market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in Treatment, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.
 
The major players in the global market Include Astellas Pharma Inc., Amgen Inc., Novartis AG, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd, Sandoz Group Ag, AbbVie Inc., strategic market developments and decisions to improve operational effectiveness.

## Recent News & Developments

August 2025: Theramex received regulatory approval across Europe and the UK for Bijuva / Bijuve, a combined hormone replacement therapy containing estradiol (1 mg) and progesterone (100 mg). It is the first and only body-identical HRT that combines both hormones in a single daily oral capsule for post-menopausal women with an intact uterus. The formulation uses hormones identical to those naturally produced in the body, offering a safer alternative to synthetic therapies, with real-world evidence indicating lower risks of venous thromboembolism, breast cancer, cardiovascular disease, and stroke. The approval also marks a significant advancement in treatment options for moderate to severe vasomotor symptoms associated with menopause.

April 2025: Real-world study of ~478,651 postmenopausal women showed Prolia reduced fracture risk vs. alendronate, including 36% lower hip fracture risk and 43% lower non-vertebral fracture risk. Risk reduction improved with longer treatment duration, reaching 31% reduction in major osteoporotic fractures by year.

March 2026: Health Canada as the first non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause. The launch is supported by the BRIGHT SKY Phase 3 program (SKYLIGHT 1, 2, and 4 trials) involving over 2,850 patients across the US, Canada, and Europe, demonstrating efficacy in reducing hot flashes and night sweats and establishing long-term safety. The therapy works via neurokinin B receptor antagonism in the hypothalamus. It has also received approvals in the US, UK, Australia, and Europe, with ongoing Phase 3 evaluation (HIGHLIGHT 1) in breast cancer patients. 

## Report Scope

| Market Menopause Stage 2024 | 16,994.32 (USD Million) |
| --- | --- |
| Market Menopause Stage 2025 | 17,628.21 (USD Million) |
| Market Menopause Stage 2035 | 30,415.70 (USD Million) |
| Compound Annual Growth Rate (CAGR) | 5.7% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Astellas Pharma Inc., Amgen Inc., Novartis AG, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd, Sandoz Group Ag, AbbVie Inc. |
| Segments Covered | By Treatment Type By Menopause Stage By Application By Distribution Channel |
| Key Market Opportunities | Development of Non-Hormonal Therapies Focus on Menopause at the Workplace. |
| Key Market Dynamics | Expanding acceptance of hormone therapy (HT) post-WHI re-evaluation Shift Towards Non-Hormonal and Dietary Supplements Growth in Online Channels & Telehealth Innovation in Delivery Systems. |
| Region Covered | North America, Europe, Asia Pacific, South America, Middle East & Africa. |

## Frequently Asked Questions

**Q: How much is the Menopause Market?**
A: USD 30,415.70 Million (2035) is the Menopause Market

**Q: What is the growth rate of the Menopause Industry?**
A: 5.7% is the growth rate of the Menopause Industry.

**Q: Which region held the largest market share in the Menopause Market?**
A: North America held the largest market share in the Menopause Market.

**Q: Who are the key players in the global Market?**
A: Astellas Pharma Inc., Amgen Inc., Novartis AG, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd, Sandoz Group Ag, AbbVie Inc are the key players in the global Market.

**Q: Which distribution Channel had the largest market share in the global Menopause Market?**
A: hospital pharmacy had the largest market share in the global Menopause Market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/menopause-market-68370*